Download Sample
Add to CartGlobal C-Reactive Protein Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Assay Type;
Immunoturbidimetric Assay and ELISA - Clinical ELISA and Nonclinical ELISA, Chemiluminescence Immunoassay, and Others.By Detection Range;
High Sensitivity C-reactive Protein (hs-CRP), Conventional CRP, and Cardiac CRP (cCRP).By Disease Area;
Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others.By End Use;
Clinics, - Clinics, by settings[Urban Settings and Rural Settings] - Urban Setting and Rural Setting, Laboratories - Urban Setting and Rural Setting, Assisted Living Healthcare Facilities - Urban Setting and Rural Setting, Home, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global C-Reactive Protein Testing Market (USD Million), 2021 - 2031
In the year 2024, the Global C-Reactive Protein Testing Market was valued at USD 1,826.25 million. The size of this market is expected to increase to USD 2,018.49 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 1.4%.
The global C-reactive protein (CRP) testing market encompasses a wide range of diagnostic tests and devices designed to measure the levels of CRP in blood samples. CRP is a biomarker indicative of inflammation and infection, and its measurement is crucial in diagnosing, monitoring, and managing various inflammatory and infectious diseases. The market for CRP testing is driven by factors such as the increasing prevalence of chronic inflammatory conditions, the growing awareness and need for early diagnosis, and advancements in testing technologies that provide rapid and accurate results.
Key players in the global CRP testing market include diagnostic companies, healthcare providers, and clinical laboratories. These stakeholders are focused on developing and commercializing innovative CRP testing solutions, ranging from high-sensitivity laboratory assays to point-of-care testing kits. The integration of CRP testing into routine clinical practice and the growing adoption of point-of-care testing devices enhance the ability of healthcare professionals to quickly assess and monitor patients' inflammatory status, leading to better clinical outcomes and more efficient disease management.
Geographically, the global CRP testing market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Each region exhibits unique market dynamics influenced by factors such as healthcare infrastructure, prevalence of inflammatory diseases, and regulatory landscapes. North America and Europe dominate the market due to their advanced healthcare systems, high adoption of innovative diagnostic technologies, and significant burden of chronic diseases. Meanwhile, the Asia Pacific region is experiencing rapid market growth driven by increasing healthcare expenditure, rising awareness about early disease diagnosis, and expanding access to medical services in emerging economies like China and India.
The global CRP testing market is poised for continued growth as the demand for reliable and rapid diagnostic tools increases. Advancements in technology, such as the development of highly sensitive and specific CRP assays, combined with the expanding applications of CRP testing in various clinical settings, will drive market expansion and innovation. As healthcare systems worldwide continue to emphasize preventive care and early diagnosis, the role of CRP testing in managing inflammation-related conditions will become increasingly vital.
Global C-Reactive Protein Testing Market Recent Developments
-
February 2023, Qlife Holding AB Launched Egoo CRP Test Sweden. This test was soft launch and will be followed by submission of application for the CE mark.
-
January 2022, LumiraDx achieved CE mark approval for its C-reactive protein PCR test. It is a compact, portable, fully-automated microfluidic immunoassay test for the quantitative detection of C-reactive protein that takes only four minutes to deliver the result.
-
July 2022, Swiss MedTech company Bloom Diagnostics launched the Bloom Inflammation Test, which measures and detects the C-Reactive Protein (CRP) in the bloodstream.
-
October 2020, Nova Biomedical introduced the Allegro CRP Test, which can be used for Point-Of-Care (POC) testing in primary care settings. This Product was launched in countries accepting CE Mark.
Segment Analysis
The global C-reactive protein (CRP) testing market is segmented by product type, including reagents, analyzers, and test kits. Reagents dominate the market due to their essential role in performing CRP tests in laboratories and healthcare settings. Analyzers, which include automated systems for testing CRP levels, are gaining popularity as they streamline testing processes and enhance the accuracy of results. Test kits are widely used for point-of-care testing, providing a convenient option for rapid CRP level assessment in clinical settings and home healthcare.
Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest market share due to the high prevalence of chronic diseases, strong healthcare infrastructure, and advancements in diagnostic technologies. Europe follows closely, with rising demand for CRP testing driven by the aging population and growing awareness of cardiovascular diseases and inflammatory conditions. Asia Pacific is expected to experience the highest growth, driven by increasing healthcare investments and rising incidences of inflammatory diseases in countries like China and India.
By end-user, the CRP testing market is segmented into hospitals, diagnostic laboratories, and home care settings. Hospitals represent the largest share, as CRP tests are critical for diagnosing infections, monitoring inflammation, and assessing cardiovascular risks in patients. Diagnostic laboratories also play a significant role, offering specialized testing services for healthcare providers. The growing trend of home healthcare is contributing to the rise in home care testing, where individuals can conduct CRP tests at home for ongoing health monitoring, especially for those with chronic conditions.
Global C-Reactive Protein Testing Segment Analysis
In this report, the Global C-Reactive Protein Testing Market has been segmented by Assay Type, Detection Range, Disease Area, End Use and Geography.
Global C-Reactive Protein Testing Market, Segmentation by Assay Type
The Global C-Reactive Protein Testing Market has been segmented by Assay Type into Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Others.
Immunoturbidimetric assays are widely used due to their simplicity, cost-effectiveness, and compatibility with automated analyzers. These assays measure CRP concentration by detecting changes in turbidity as CRP forms immune complexes with specific antibodies. Immunoturbidimetric assays are well-suited for high-throughput clinical laboratories, providing rapid and reliable results essential for diagnosing and monitoring inflammatory conditions.
ELISA is another prevalent assay type in the CRP testing market, known for its high sensitivity and specificity. This method involves immobilizing CRP antibodies on a microplate, capturing CRP from patient samples, and using enzyme-linked detection antibodies to produce a measurable signal. ELISA assays are extensively utilized in both clinical and research settings, offering robust performance and quantitative results that aid in detailed inflammatory status assessment. ELISA's versatility and accuracy make it a preferred choice for comprehensive CRP analysis, especially in scenarios requiring precise quantification. Chemiluminescence immunoassays (CLIAs) represent a more advanced assay type in the CRP testing market, leveraging chemiluminescent labels to detect CRP levels with high sensitivity and specificity. CLIAs offer enhanced signal detection and broader dynamic range compared to traditional immunoassays, facilitating the detection of low CRP concentrations in various clinical conditions. These assays are particularly valuable in high-sensitivity CRP testing, which is critical for cardiovascular risk assessment and early detection of systemic inflammation.
Global C-Reactive Protein Testing Market, Segmentation by Detection Range
The Global C-Reactive Protein Testing Market has been segmented by Detection Range into High Sensitivity C-reactive Protein (hs-CRP), Conventional CRP and Cardiac CRP (cCRP).
High sensitivity CRP (hs-CRP) assays are designed to detect very low levels of CRP in the blood, often in the range of 0.5 to 10 mg/L. This high sensitivity is particularly useful in cardiovascular disease risk assessment, as even slight elevations in CRP can indicate a higher risk of cardiovascular events. Hs-CRP testing is widely adopted in preventive cardiology to identify individuals at risk for heart disease and to guide lifestyle and therapeutic interventions aimed at reducing cardiovascular risk.
Conventional CRP assays, on the other hand, measure CRP levels in a broader range, typically from 10 to 1000 mg/L, making them suitable for diagnosing and monitoring acute inflammatory conditions and infections. These assays are commonly used in clinical settings to assess the severity of bacterial infections, autoimmune diseases, and other inflammatory disorders. By providing rapid and accurate measurement of CRP levels, conventional CRP tests help healthcare providers diagnose conditions like sepsis, rheumatoid arthritis, and inflammatory bowel disease, and monitor the effectiveness of treatment strategies.
Cardiac CRP (cCRP) assays are specifically tailored for assessing inflammation related to cardiovascular health, combining elements of both hs-CRP and conventional CRP testing. These assays are used to evaluate chronic low-grade inflammation associated with atherosclerosis and other cardiovascular conditions. cCRP testing aids in the early detection of cardiovascular diseases, allowing for timely intervention and management to prevent adverse cardiovascular events.
Global C-Reactive Protein Testing Market, Segmentation by Disease Area
The Global C-Reactive Protein Testing Market has been segmented by Disease Area into Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Others.
In cardiovascular diseases, CRP testing, particularly high-sensitivity CRP (hs-CRP) assays, is crucial for assessing the risk of atherosclerosis, myocardial infarction, and other cardiovascular conditions. Elevated CRP levels can indicate systemic inflammation, a key factor in the development and progression of cardiovascular diseases. As a result, CRP testing is integral to preventive cardiology, guiding risk stratification and therapeutic interventions to mitigate cardiovascular risk. Cancer is another critical area where CRP testing plays a significant role. Elevated CRP levels can be indicative of inflammation associated with tumor growth and metastasis. CRP testing aids in monitoring disease progression, treatment response, and prognosis in cancer patients. Similarly, in rheumatoid arthritis, CRP levels are used to assess disease activity and inflammation, guiding treatment decisions and monitoring the effectiveness of therapeutic interventions. Regular CRP testing in rheumatoid arthritis patients helps clinicians adjust treatment plans to manage symptoms and prevent disease flares effectively.
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal tract. CRP testing is a valuable tool for monitoring disease activity, guiding treatment, and assessing the response to therapies in IBD patients. Endometriosis, a condition marked by the presence of endometrial tissue outside the uterus, also shows elevated CRP levels during inflammatory episodes, aiding in diagnosis and management. Lupus, a systemic autoimmune disease, involves chronic inflammation affecting multiple organs, with CRP levels serving as an important marker for disease activity and flare-ups.
Global C-Reactive Protein Testing Market, Segmentation by End Use
The Global C-Reactive Protein Testing Market has been segmented by End Use into Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Others.
Clinics represent a significant end-use segment, comprising outpatient facilities, primary care clinics, and specialty clinics. In these settings, CRP testing is often performed to aid in the diagnosis and monitoring of various acute and chronic conditions, including infections, inflammatory diseases, and cardiovascular disorders. CRP testing in clinics facilitates timely clinical decision-making and treatment planning, ensuring optimal patient care and management of inflammatory conditions.
Hospitals constitute another key end-use segment in the CRP testing market, encompassing a wide range of healthcare facilities, from community hospitals to large tertiary care centers. In hospital settings, CRP testing is integral to the diagnostic workup of patients presenting with a diverse array of medical conditions, ranging from infectious diseases and autoimmune disorders to cardiovascular events and post-operative complications. CRP testing in hospitals supports multidisciplinary care teams in assessing disease severity, monitoring treatment response, and guiding therapeutic interventions, ultimately improving patient outcomes and reducing healthcare costs.
Laboratories play a pivotal role in the CRP testing market, serving as centralized facilities for conducting diagnostic tests and providing accurate and timely results to healthcare providers. Clinical laboratories, including independent diagnostic laboratories and hospital-based laboratories, perform a wide range of CRP tests using automated analyzers and standardized protocols. Assisted living healthcare facilities, including long-term care facilities and nursing homes, utilize CRP testing to monitor residents' health status and detect early signs of infection or inflammation. Additionally, CRP testing in home settings is gaining popularity, driven by the increasing availability of point-of-care testing devices that enable patients to monitor their CRP levels conveniently and efficiently.
Global C-Reactive Protein Testing Market, Segmentation by Geography
In this report, the Global C-Reactive Protein Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global C-Reactive Protein Testing Market Share (%), by Geographical Region, 2024
North America and Europe stand as the dominant regions in this market, attributed to their well-established healthcare infrastructure, high prevalence of chronic diseases, and extensive adoption of advanced diagnostic technologies. These regions witness significant demand for CRP testing due to the rising incidence of inflammatory conditions, such as cardiovascular diseases, autoimmune disorders, and infectious diseases.
The Asia Pacific region is experiencing rapid market growth fueled by factors such as increasing healthcare expenditure, growing awareness about preventive healthcare, and expanding access to diagnostic services in emerging economies like China, India, and Southeast Asian countries. The Middle East and Africa, along with Latin America, represent emerging markets with substantial growth potential in the CRP testing market. These regions are witnessing increasing investments in healthcare infrastructure, rising healthcare awareness among the population, and government initiatives to improve healthcare access and quality.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global C-Reactive Protein Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis, Market Opportunity Mapping, PEST (Political, Economic, Social and Technological) Analysis and Porter's Five Forces Analysis.
Drivers, Restraints and Opportunities
Drivers
- Increasing Prevalence of Chronic Diseases
- Advancements in Diagnostic Technologies
-
Increasing Healthcare Expenditure and Awareness: The growing healthcare expenditure, particularly notable in developing regions, is playing a pivotal role in propelling the CRP testing market forward. As these regions witness economic growth and improvements in healthcare infrastructure, there's a notable shift towards prioritizing preventive healthcare measures. Governments and healthcare organizations are increasingly advocating for early diagnosis and proactive health management strategies. This emphasis translates into comprehensive health screening programs that encompass CRP testing as a routine component. By integrating CRP testing into regular health check-ups, healthcare providers can swiftly identify potential inflammatory markers, enabling timely interventions and disease management.
Public awareness campaigns are contributing significantly to the market's expansion. These campaigns aim to educate individuals about the significance of monitoring inflammation levels for early detection of underlying health conditions. By raising awareness about the role of CRP testing in identifying potential health risks, these initiatives empower individuals to take proactive steps towards maintaining their well-being. Consequently, the combination of growing healthcare expenditure, coupled with increased awareness about preventive healthcare measures, is fostering a conducive environment for the widespread adoption of CRP testing as a crucial tool in preventive medicine.
Restraints
- High Cost of Advanced Testing Methods
- Limited Awareness and Accessibility in Developing Regions
-
Potential for False Positives/Negatives: While CRP testing serves as a valuable indicator of inflammation within the body, its limitations regarding disease specificity present challenges in clinical interpretation. CRP levels can be elevated in response to various stimuli, including infections, injuries, and non-specific inflammatory conditions. This lack of specificity means that elevated CRP levels do not always indicate a particular disease or condition, and conversely, normal CRP levels do not necessarily rule out underlying health issues. As a result, clinicians must exercise caution when interpreting CRP test results to avoid misdiagnosis or inappropriate treatment decisions.
The potential for false positives or negatives in CRP testing underscores the need for complementary diagnostic methods and clinical evaluation. While elevated CRP levels may prompt further investigation, such as imaging or additional laboratory tests, they should be interpreted alongside the patient's clinical history and other relevant diagnostic findings. Likewise, normal CRP levels do not exclude the possibility of underlying pathology, necessitating a comprehensive approach to patient assessment. Despite these limitations, CRP testing remains a valuable tool in clinical practice, particularly when used judiciously in conjunction with other diagnostic modalities to inform patient care decisions accurately.
Opportunities
- Expansion into Emerging Markets
- Integration with Digital Health Technologies
-
Personalized Medicine and Predictive Diagnostics: The shift towards personalized medicine and predictive diagnostics represents a significant paradigm in healthcare, leveraging CRP testing among other biomarkers to customize treatment approaches for individual patients. By incorporating CRP levels into a broader panel of biomarkers, clinicians can gain deeper insights into a patient's inflammatory status and overall health profile. This comprehensive assessment enables healthcare providers to tailor treatment plans to suit the specific needs and risks of each patient, optimizing therapeutic outcomes and minimizing adverse effects.
The integration of CRP testing into predictive diagnostics holds promise for identifying individuals at heightened risk of disease flare-ups or complications. By monitoring CRP levels over time and correlating them with clinical outcomes, healthcare providers can anticipate disease progression and intervene preemptively to mitigate risks. This proactive approach aligns with the principles of precision healthcare, emphasizing early intervention and targeted therapies tailored to each patient's unique physiological and genetic makeup. Consequently, the growing emphasis on personalized medicine is driving the evolution of CRP testing technologies and applications, fostering innovation in diagnostic methods and analytical platforms to meet the demands of increasingly individualized patient care.
Competitive Landscape Analysis
Key players in Global C-Reactive Protein Testing Market include
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher
- Quest Diagnostics Incorporated
- Siemens
- Abbott Laboratories
- Laboratory Corporation of America Holdings (LabCorp)
- Merck KGaA
- Abaxis, Inc.
- Ortho Clinical Diagnostics
- Getein Biotech, Inc.
- HORIBA, Ltd.
- Randox Laboratories Ltd.
- BODITECH MED, INC
- Aidian
- Eurolyser Diagnostica GmbH
- Abcam plc
- Bio-Techne
- EKF Diagnostics
- SD Biosensor, INC.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Assay Type
- Market Snapshot, By Detection Range
- Market Snapshot, By Disease Area
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global C-Reactive Protein Testing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Chronic Diseases
- Advancements in Diagnostic Technologies
- Increasing Healthcare Expenditure and Awareness
- Restraints
- High Cost of Advanced Testing Methods
- Limited Awareness and Accessibility in Developing Regions
- Potential for False Positives/Negatives
- Opportunities
- Expansion into Emerging Markets
- Integration with Digital Health Technologies
- Personalized Medicine and Predictive Diagnostics
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global C-Reactive Protein Testing Market, By Assay Type, 2021 - 2031 (USD Million)
- Immunoturbidimetric Assay
- ELISA
- Clinical ELISA
- Nonclinical ELISA
- Chemiluminescence Immunoassay
- Others
- Global C-Reactive Protein Testing Market, By Detection Range, 2021 - 2031 (USD Million)
- High Sensitivity C-reactive Protein (hs-CRP)
- Conventional CRP
- Cardiac CRP (cCRP)
- Global C-Reactive Protein Testing Market, By Disease Area, 2021 - 2031 (USD Million)
- Cardiovascular Diseases
- Cancer
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
- Endometriosis
- Lupus
- Others
- Global C-Reactive Protein Testing Market, By End Use, 2021 - 2031 (USD Million)
- Clinics
- Physician Offices
- Small Clinics
- Others
- Clinics, by settings
- Urban Settings
- Rural Settings
- Hospitals
- Urban Setting
- Rural Setting
- Laboratories
- Urban Setting
- Rural Setting
- Assisted Living Healthcare Facilities
- Urban Setting
- Rural Setting
- Home
- Others
- Clinics
- Global C-Reactive Protein Testing Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global C-Reactive Protein Testing Market, By Assay Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher
- Quest Diagnostics Incorporated
- Siemens
- Abbott Laboratories
- Laboratory Corporation of America Holdings (LabCorp)
- Merck KGaA
- Abaxis, Inc.
- Ortho Clinical Diagnostics
- Getein Biotech, Inc.
- HORIBA, Ltd.
- Randox Laboratories Ltd.
- BODITECH MED, INC
- Aidian
- Eurolyser Diagnostica GmbH
- Abcam plc
- Bio-Techne
- EKF Diagnostics
- SD Biosensor, INC.
- Company Profiles
- Analyst Views
- Future Outlook of the Market